戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ents are incurable and become candidates for investigational therapy.
2  uncontrolled trials may bias them toward an investigational therapy.
3  committee had no record of approval for the investigational therapy.
4 ney injury in IgAN and a possible target for investigational therapy.
5 rGBM's evolution during administration of an investigational therapy.
6 uville 4 should be the focus of risk-adapted investigational therapies.
7 agnosis and management of food allergies and investigational therapies.
8 ir potential to be targeted with approved or investigational therapies.
9 changes as shown by the mfVEP in response to investigational therapies.
10 t from having a liver biopsy and considering investigational therapies.
11 ation TKIs to combination regimens and other investigational therapies.
12 reatment approaches with a focus on emerging investigational therapies.
13  2019), and medical treatment including four investigational therapies.
14 empirical antibiotics; and 23 (85%) received investigational therapies (19 [70%] received at least tw
15 tients elected standard of care (SOC) (103), investigational therapy (28) or palliative care (40); 9
16 and the immune system have led to many novel investigational therapies and continue to inform efforts
17 bility to determine the potential benefit of investigational therapies and the effect of patient-spec
18 cting patient safety, facilitating access to investigational therapies, and ensuring trial integrity.
19 predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping
20 e relative contributions of supportive care, investigational therapies, and patient's immune-response
21                      Monoclonal and cellular investigational therapies are quite promising and should
22 ioned due to a lower response rate and newer investigational therapies are reported.
23           Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered
24 ide a rationale for the continued testing of investigational therapies, confirm the effectiveness of
25 ed cancer cells in PA, with implications for investigational therapies directed at this pathway.
26 rams that choose to change patients to other investigational therapies (eg, intensive chemotherapy an
27 exclusion criteria were concurrent or recent investigational therapy, evidence of bowel obstruction,
28 ions were observed for patients who received investigational therapy followed by cisplatin-based ther
29            In 2018, a clinical trial of four investigational therapies for Ebola virus disease (EVD),
30 nvasive monitoring, vasopressor support, and investigational therapies for Ebola virus disease.
31                 We conducted a trial of four investigational therapies for EVD in the Democratic Repu
32 us accruing sites in a complex trial to test investigational therapies for moderately frequent molecu
33           The in vivo preclinical testing of investigational therapies for multiple myeloma (MM) is h
34 gets for many of the currently available and investigational therapies for this condition.
35  patients receiving 131I anti-B1 therapy, an investigational therapy for non-Hodgkin's lymphoma, indi
36 tudy evaluated the efficacy and safety of an investigational therapy for severe VKC, cyclosporine A (
37         The clinical activity of these newer investigational therapies has been mixed, with some ther
38                          Recently, a wave of investigational therapies has come under evaluation, inc
39 t, in general, older patients should receive investigational therapy; however, factors other than age
40                                        Novel investigational therapies in clinical development includ
41 l trials are needed to delineate the role of investigational therapies in the care of patients with E
42                                          The investigational therapy involved infusion of autologous
43                                          The investigational therapy involved infusion of autologous
44                          In some cases where investigational therapy is unavailable, palliative care
45 anut oral immunotherapy (OIT) is a promising investigational therapy, its potential is limited by sub
46 nical trials for measuring the benefit of an investigational therapy on a patient's vision-related an
47  current treatment and are better suited for investigational therapy or supportive care.
48 consent for a trial but before receiving the investigational therapy, participants answered questions
49 an papillomavirus-negative HNSCC, as well as investigational therapies, such as hypoxia modification,
50 helf, allogeneic, multivirus-specific T-cell investigational therapy targeting BK virus, as well as f
51 gnaling are reviewed along with an update on investigational therapies that use this pathway to rever
52 ications for the application of standard and investigational therapies to patients with ADA-SCID and
53 alamic deep brain stimulation (CT-DBS) is an investigational therapy to treat enduring cognitive dysf
54                                              Investigational therapies under development for WM inclu
55 onsultation, options for standard as well as investigational therapies were discussed, and HLA typing
56                          Initial results for investigational therapies were mixed.
57  7 of the 11 patients (64%) who received the investigational therapy were in ongoing remission at 3 t
58  of study provisions that allow crossover to investigational therapy when benefit has been clearly de
59 ory CME remains a therapeutic challenge, but investigational therapies with potential include cortico